Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | TACR2 | P21452 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27823063 | 0.78 | LIPG (0.40) | HTR2ACA2KDM4EALDH1A1ESR1 | |
| SCHEMBL3919456 | 0.78 | ALDH1A1 (0.36) | HTR2ACA2KDM4EALDH1A1ESR1 | |
| SCHEMBL4722781 | 0.76 | — | — | |
| SCHEMBL3312949 | 0.76 | PTGS2 (0.42) | CA2KDM4EALDH1A1ESR1ADRA2A | |
| SCHEMBL28522920 | 0.76 | LIPG (0.43) | HTR2AKDM4EALDH1A1ESR1ADRA2A | |
| SCHEMBL10652440 | 0.74 | PTGS2 (0.46) | KDM4EALDH1A1ESR1ADRA2AADORA3 | |
| SCHEMBL18825694 | 0.74 | LIPG (0.38) | HTR2ACA2KDM4EALDH1A1ESR1 | |
| SCHEMBL23616887 | 0.72 | — | — | |
| SCHEMBL16844660 | 0.72 | LIPG (0.39) | HTR2AKDM4EALDH1A1ESR1ADRA2A | |
| SCHEMBL26972082 | 0.72 | HSD11B1 (0.35) | HTR2ACA2KDM4EALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106008665-B | Compound with tumor proliferation inhibition function and preparation method and application thereof | 北京大学 | 2021-03-16 | — | — | CN | disclosed |
| US-7625915-B2 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER HEALTHCARE LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | DUMAS JACQUES | 2008-12-04 | — | — | US | disclosed |
| EP-1043995-B9 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7329670-B1 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080009527-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2008-01-10 | — | — | US | disclosed |
| EP-1043995-B1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1043995-A4 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1056725-A4 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1056725-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1043995-A1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999032110-A1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032455-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | MAPK1, MAP3K1, MAP3K2 | HTR2A 3827/4885CA2 4263/4885SKP2 648/4885 |
| US-20080009527-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | HTR2A 4212/4885CA2 4323/4885SKP2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.